· Published by Health Canada · Official notice
This is duplicated text of a letter from GlaxoSmithKline Inc.
Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
May 3, 2012
Dear Health Care Professional,
Subject: Association of BENLYSTA™ (belimumab) with hypersensitivity and infusion reactions
GlaxoSmithKline Inc., in consultation with Health Canada, would like to inform you of important new safety information related to hypersensitivity and infusion reactions associated with BENLYSTA™ (belimumab) treatment.
BENLYSTA™ is indicated, in addition to standard therapy, for reducing disease activity in adult patients with active, autoantibody-positive, systemic lupus erythematosus (SLE). At the time of authorization, the Product Monograph included information and warnings related to a reported higher incidence of hypersensitivity reactions in treated patients compared to placebo.
After the review of post-marketing reports, the Product Monograph for BENLYSTATM has been updated with new safety information that you need to be aware of. Other countries have made similar labeling changes.
Important information for healthcare professionals:
Healthcare professionals are reminded that:
Recently, a number of post-marketing reports concerning serious acute hypersensitivity reactions have been received globally. Some of these appear to have been delayed beyond what had been observed in previous clinical trials where most events happened during or very shortly after completion of the infusion. Development of acute symptoms several hours after the infusion (i.e. in the evening on the day the drug was administered), has been reported. One patient, with a history of multiple drug allergies, died after developing dyspnea, respiratory distress, hypoxia and angioedema following the second infusion of belimumab. The onset of symptoms was suspected to have begun approximately 4 hours after the end of belimumab infusion.
The updated Product Monograph for BENLYSTA™ is available on the Canadian web site of GlaxoSmithKline. Any questions from healthcare professionals may be directed to our Medical Information department via GSK Customer Service at 1-800-387-7374.
Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any case of serious hypersensitivity and infusion reactions, or other serious or unexpected adverse reactions in patients receiving BENLYSTA™ should be reported to GlaxoSmithKline Inc. or Health Canada.
GlaxoSmithKline Inc.
7333 Mississauga Road
Mississauga, Ontario
L5N 6L4
Tel: 1-800-387-7374
To correct your mailing address or fax number, also contact GlaxoSmithKline Inc.
To report suspected adverse reactions to these or other health products, please contact Health Canada's Canada Vigilance Program toll-free at 1-866-234-2345, or visit the MedEffectTM Canada Web site for information on how to report.
The Reporting Forms, postage paid labels, and Guidelines can be found on the MedEffectTM Canada Web site in the Adverse Reaction Reporting section. The Reporting Form is also in the Canadian Compendium of Pharmaceuticals and Specialties.
For other health product inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate
E-mail: mhpd_dpsc.public@hc-sc.gc.ca
Telephone: 613-954-6522
Fax: 613-952-7738
Sincerely,
original signed by
Dr. Glenn Crater,
Vice-President, Medical and Chief Medical Officer
™BENLYSTA is a trademark of Human Genome Sciences, Inc., used under license by GlaxoSmithKline Inc.